TEP study targets prefrontal-occipital divergence in DLB and AD

A forthcoming paper in Clinical EEG and Neuroscience applies transcranial magnetic stimulation to one of neurology's more stubborn diagnostic problems. The study, posted Ahead of Print under the title "Prefrontal and Occipital Network Excitability Differences in Dementia with Lewy Bodies and Alzheimer's Disease," uses TMS-evoked potentials to compare cortical physiology across two dementia populations.

What did the team measure?

The method is perturbational rather than observational. A single TMS pulse is delivered to a scalp target; the EEG response that follows, the TEP, indexes the local circuit's capacity to excite and inhibit. By stimulating prefrontal and occipital sites and recording the resulting potentials, the authors compared how each region handles a controlled input in DLB versus AD.

The opening background of the paper states the problem bluntly: there is "a great need in distinguishing Dementia with Lewy Body from Alzheimer's disease and elucidating its pathophysiology." TEPs, the authors add, "offer a non-invasive measure" of that pathophysiology, a feature that matters in patients who may tolerate repeated testing poorly.

Why does the prefrontal-occipital pair interest the researchers?

Prefrontal cortex carries the executive and attentional load that falters early in both diseases. Occipital cortex sits at the center of the visual processing failures that mark DLB. Comparing the two regions captures the spatial signature of each illness. AD tends to erode posterior association cortex gradually. DLB strikes earlier in parietal-occipital networks. A TEP that lights up differently in those two territories could function as a circuit-level fingerprint.

What does this change for clinicians?

For now, nothing in the standard workflow. TEPs require a TMS coil, a compatible EEG amplifier, and a technician willing to deliver dozens of single pulses at fixed intensity while a patient holds still. Few memory clinics outside research centers have the kit. If the reported pattern survives peer review and replicates across cohorts, TMS-EEG would move onto the same shelf as DaT-SPECT and CSF alpha-synuclein assays, used when the clinical picture stays ambiguous.

That shelf is currently narrow. AD diagnosis rests on amyloid and tau biomarkers. DLB diagnosis still leans on clinical consensus criteria plus optional dopamine-transporter imaging. An electrophysiology test that distinguishes the two cheaply and without radiation would address a real gap, particularly in earlier or atypical presentations where the two entities blur.

What should the reader watch for?

The Ahead of Print label means the manuscript has been accepted but not yet assigned to an issue. Key questions will be the cohort size, whether the prefrontal and occipital TEP differences survive correction for multiple comparisons, and how the authors handled the cholinergic medications most DLB patients take. Cholinesterase inhibitors shift cortical excitability on their own, and any DLB-AD comparison that ignores them risks attributing drug effects to disease.

Watch the full publication date. If the signal replicates at modest sample size, TMS-EEG may join the small toolkit of biomarkers that can be deployed in a tertiary memory clinic without a cyclotron or a lumbar puncture.